.Nature Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ sophisticated breast cancer and energetic or even secure mind metastases showed regular intracranial task and systemic efficiency of T-DXd.